Brain Cancer Clinical Trials

Brain: Treatment Trials


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Cancer Clinical Trials

Breast: Treatment Trials 


Study Title: An open label randomized phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: AFT-38 – PATINA - Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive
Primary/Site/Co-Investigator: Peter Kaufman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Primary/Site/Co-Investigator: Carl Nelson, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

 Breast: Symptom Management & Quality of Life Trials


Study Title: A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Bladder Cancer Clinical Trials

Bladder: Treatment Trials 


Study Title: D933RC00001- NIAGARA-A Phase III Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine & Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475 in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cander (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Primary/Site/Co-Investigator: Scott Perrapato, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Endometrial/Uterine Cancer Clinical Trials

Endometrial/Uterine: Treatment Trials


Study Title: A Phase III Randomized, Placebo-Controlled Study Of Pembrolizumab (MK-3475, NSC #776864) In Addition To Paclitaxel And Carboplatin For Measurable Stage III Or IVA, Stage IVB Or Recurrent Endometrial Cancer
Primary/Site/Co-Investigator: Evelyn Cantillo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Head and Neck Cancer Clinical Trials

Nead and Neck: Treatment Trials


Study Title: MK-3475-689-A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Primary/Site/Co-Investigator: Mirabelle Sajisevi, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Kidney Cancer Clinical Trials

Kidney: Treatment Trials


Study Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab:  A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
Primary/Site/Co-Investigator: Shahid Ahmed, MBBS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Leukemia Cancer Clinical Trials

Leukemia: Treatment Trials


Study Title: D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage
Primary/Site/Co-Investigator: Sakshi Jasra, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Cancer Clinical Trials

Lung: Treatment Trials


Study Title: D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC4/RTOG-3515)
Primary/Site/Co-Investigator: Nat Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG-LU005 Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
Primary/Site/Co-Investigator: Chris Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1800: Pilot Study involving Active Surveillance with CT Imaging and Liquid Biopsies For Inoperable Stage IA Lung Cancer in the Elderly
Primary/Site/Co Investigator: Christopher Anker, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA5163 - A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lymphoma Clinical Trials

Lymphoma: Treatment Trials 


Study Title: A051701: Randomiized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoinnumotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas
Primary/Site/Co-Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: Genentech ML29496: Maintenance Obinutuzumab for primary Central Nervous System Lymphoma Complete Responders
Primary/Site/Co Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Primary/Site/Co Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Melanoma Clinical Trials

Melanoma: Treatment Trials 


Study Title: A071701 Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: ECOG EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Cancer Sites Clinical Trials

Multiple Cancer Sites: Symptom Management & Quality of Life


Study Title: EPIPHANY 10001-Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Primary/Site/Co-Investigator:Noah Kolb, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: UVMCC 1518 (VTE-PACC): VTE Prophylaxis in the Ambulatory Cancer Clinic (VTE-PACC)
Primary/Site/Co-Investigator: Chris Holmes, MD, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: A221602: Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial
Primary/Site/Co-Investigator: Steven Ades, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Ovarian Cancer Clinical Trials

Ovarian: Treatment Trials 


Study Title: VBL-111-701, GOG 3018 OVAL - The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Primary/Site/Co-Investigator: Evelyn Cantillo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Prostate Cancer Clinical Trials

Prostate: Treatment Trials

 

Study Title: S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) or the Primary Tumor in Metastatic Prostate Cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Rectum Cancer Clinical Trials

Rectum: Treatment Trials


Study Title: NRG GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Study Title: EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Other Ways to Help Advance Cancer Research


Study Title: UVMCC 1904 Tissue Bank for Benign and Malignant Tumors of the Nervous System
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Study Title: UVMCC 1515: Assessment of intrinsic fluorescence as a diagnostic tool for breast cancer tumors and nodal involvement
Primary/Site/Co Investigator: Gary Stein, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Study Title: VCC 1106: Tumor Binding Antibodies from Cancer Patients
Primary/Site/Co Investigator: David Krag, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast & Ovarian Study Title: V0308:  Clinical and Molecular Markers of Risk for Breast and Ovarian Cancers
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Study Title: UVMCC 1704: The DNA Repair Landscape of Women at Risk for Breast Cancer: Family Studies Companion
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Study Title: VCC 1205: The DNA Repair Landscape of Women at Risk for Breast Cancer
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Study Title: A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2 or Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Colon Cancer Study Title: UVMCC 1901, Use of digital PET scanning to identify lymphatic metastases in colon cancer
Primary/Site/Co Investigator: Peter Cataldo, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Sites Study Title:  VCC 1107: Oncology Rehabilitation Database
Primary/Site/Co Investigator: Kim Dittus, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

About Us

FAQs

Contact Us

 

Trials by Cancer Type

Click below to view open cancer trials by type. 

Brain Breast Bladder Endometrial/Uterine Head and Neck Kidney Leukemia Lung Lymphoma Melanoma Multiple Sites Ovarian Pediatric Prostate Rectum Other Ways to Help Advance Cancer Research

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4414 ext. 2.